{"id":"nmn","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL610238","moleculeType":"Small molecule","molecularWeight":"334.22"},"_dailymed":{"setId":"2468429b-8376-8054-e063-6394a90aa2ee","title":"RESVERATROL NMN COLLAGEN SERUM LIQUID [DONGGUAN HAIYI TECHNOLOGY CO.,LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NMN is a precursor to NAD+ (nicotinamide adenine dinucleotide), a critical coenzyme involved in cellular energy production, DNA repair, and stress response pathways. By increasing intracellular NAD+ availability, NMN aims to enhance mitochondrial function, improve metabolic efficiency, and support cellular resilience in aging-related conditions. This mechanism is thought to activate sirtuins and other NAD+-dependent enzymes that regulate longevity and metabolic health.","oneSentence":"NMN (nicotinamide mononucleotide) replenishes cellular NAD+ levels to support mitochondrial function and energy metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:19:16.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related metabolic decline"},{"name":"Mitochondrial dysfunction support"}]},"trialDetails":[{"nctId":"NCT04571008","phase":"NA","title":"Effect of NMN Supplementation on Organ System Biology","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-10-01","conditions":"Glucose Metabolism Disorders","enrollment":56},{"nctId":"NCT07451496","phase":"NA","title":"PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-09-29","conditions":"Ageing","enrollment":20},{"nctId":"NCT07144527","phase":"NA","title":"Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","status":"RECRUITING","sponsor":"Scott Silveira","startDate":"2026-02-21","conditions":"Aging, Frailty, Exercise Tolerance","enrollment":40},{"nctId":"NCT07013591","phase":"PHASE2","title":"Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-03-31","conditions":"Coronary Artery Bypass Graft","enrollment":90},{"nctId":"NCT05759468","phase":"PHASE2","title":"NAD Augmentation in Diabetes Kidney Disease","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-04-13","conditions":"Type2diabetes, Diabetic Kidney Disease","enrollment":140},{"nctId":"NCT05878119","phase":"PHASE2","title":"Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2023-10-25","conditions":"Healthy","enrollment":124},{"nctId":"NCT07278492","phase":"PHASE1","title":"NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-04-01","conditions":"Down Syndrome (DS)","enrollment":24},{"nctId":"NCT05305677","phase":"NA","title":"Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2022-06-01","conditions":"Polycystic Ovary Syndrome","enrollment":88},{"nctId":"NCT06776510","phase":"PHASE1, PHASE2","title":"A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-15","conditions":"Immune Thrombocytopenia, Treatment","enrollment":20},{"nctId":"NCT06907329","phase":"NA","title":"The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.","status":"RECRUITING","sponsor":"Qing Su","startDate":"2025-06-05","conditions":"Immunosenescence, Metabolism","enrollment":126},{"nctId":"NCT06889740","phase":"NA","title":"Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants","status":"COMPLETED","sponsor":"EffePharm LTD","startDate":"2024-07-08","conditions":"Healthy Aging","enrollment":80},{"nctId":"NCT06592859","phase":"NA","title":"Quzhou Population Cohort Research Project (Aging Related Research: Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People)","status":"RECRUITING","sponsor":"People's Hospital of Quzhou","startDate":"2023-08-23","conditions":"Aging, NMN","enrollment":240},{"nctId":"NCT06991712","phase":"PHASE2","title":"Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients","status":"RECRUITING","sponsor":"Christopher Kai Shun Leung","startDate":"2025-05-19","conditions":"Glaucoma","enrollment":138},{"nctId":"NCT06966583","phase":"PHASE1","title":"NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-05-01","conditions":"Solid Tumor, Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT06882096","phase":"PHASE1","title":"Tracing the Metabolic Flux of Orally Administered NAD+ Precursors","status":"RECRUITING","sponsor":"Metro International Biotech, LLC","startDate":"2025-04-28","conditions":"Healthy Adults","enrollment":32},{"nctId":"NCT05517122","phase":"NA","title":"Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2022-07-12","conditions":"Healthy","enrollment":68},{"nctId":"NCT05882214","phase":"PHASE1, PHASE2","title":"Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink","status":"COMPLETED","sponsor":"Zhejiang Chinese Medical University","startDate":"2024-05-01","conditions":"Binge Drinking, Liver Injury, Nutritional Supplementation","enrollment":22},{"nctId":"NCT06889142","phase":"NA","title":"Impact of NMN Supplementation on CD4+ T Cell Recovery in HIV Patients With Immunological Failure","status":"NOT_YET_RECRUITING","sponsor":"TriHealth Inc.","startDate":"2025-04","conditions":"Human Immunodeficiency Virus","enrollment":7},{"nctId":"NCT05698771","phase":"PHASE1","title":"NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2022-09-17","conditions":"Healthy","enrollment":12},{"nctId":"NCT06739720","phase":"PHASE2, PHASE3","title":"RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-01-02","conditions":"Chronic Fatigue Syndrome (CFS), Post-COVID ME/CFS","enrollment":130},{"nctId":"NCT06629636","phase":"NA","title":"Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.","status":"RECRUITING","sponsor":"Sunkaky Medical Cooperation","startDate":"2024-08-20","conditions":"Repeated IVF Failure, Female Infertility","enrollment":60},{"nctId":"NCT05175768","phase":"NA","title":"Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection","status":"TERMINATED","sponsor":"Vedic Lifesciences Pvt. Ltd.","startDate":"2021-12-27","conditions":"COVID-19 Infection","enrollment":69},{"nctId":"NCT06426355","phase":"NA","title":"The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-10-01","conditions":"Diminished Ovarian Reserve","enrollment":200},{"nctId":"NCT05295342","phase":"NA","title":"The No Means No South Africa Evaluation Study","status":"COMPLETED","sponsor":"RTI International","startDate":"2022-02-16","conditions":"Gender-based Violence, Sexual Violence","enrollment":2173},{"nctId":"NCT06214078","phase":"NA","title":"Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis","status":"UNKNOWN","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-02-01","conditions":"Ulcerative Colitis Chronic Mild","enrollment":48},{"nctId":"NCT04664361","phase":"NA","title":"Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity","status":"COMPLETED","sponsor":"Seneque SA","startDate":"2021-03-09","conditions":"Physical Activity, Muscle Recovery","enrollment":131},{"nctId":"NCT06036355","phase":"EARLY_PHASE1","title":"The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)","status":"UNKNOWN","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","startDate":"2023-09-30","conditions":"Postoperative Prevention of Tumor","enrollment":20},{"nctId":"NCT05984550","phase":"EARLY_PHASE1","title":"The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.","status":"UNKNOWN","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","startDate":"2023-08","conditions":"Enhance Immune Function","enrollment":10},{"nctId":"NCT04910061","phase":"NA","title":"Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.","status":"COMPLETED","sponsor":"Seneque SA","startDate":"2021-08-05","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04862338","phase":"NA","title":"Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults","status":"COMPLETED","sponsor":"Seneque SA","startDate":"2021-04-26","conditions":"Healthy Volunteers","enrollment":17},{"nctId":"NCT05485610","phase":"NA","title":"Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency)","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-07-01","conditions":"Diminished Ovarian Reserve, Premature Ovarian Insufficiency","enrollment":200},{"nctId":"NCT04903210","phase":"PHASE4","title":"Nicotinamide Mononucleotide in Hypertensive Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-06-01","conditions":"Hypertension","enrollment":20},{"nctId":"NCT04823260","phase":"NA","title":"To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults","status":"COMPLETED","sponsor":"Abinopharm, Inc","startDate":"2021-05-25","conditions":"Aging","enrollment":90},{"nctId":"NCT03151239","phase":"NA","title":"Effect of \"Nicotinamide Mononucleotide\" (NMN) on Cardiometabolic Function","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-07-01","conditions":"Glucose Metabolism Disorders","enrollment":25},{"nctId":"NCT04685096","phase":"","title":"Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo","status":"COMPLETED","sponsor":"Seneque SA","startDate":"2020-12-12","conditions":"Wrinkle, Fatigue, Puffiness Around the Eyes","enrollment":89},{"nctId":"NCT04228640","phase":"NA","title":"Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3)","status":"COMPLETED","sponsor":"EffePharm LTD","startDate":"2020-12-15","conditions":"Aging","enrollment":66}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL DISTENSION"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"APPENDICITIS"},{"count":1,"reaction":"APPENDICITIS PERFORATED"},{"count":1,"reaction":"BRAIN FOG"},{"count":1,"reaction":"CHROMATURIA"},{"count":1,"reaction":"COGNITIVE DISORDER"},{"count":1,"reaction":"DEPRESSED MOOD"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DRUG INTERACTION"}],"_approvalHistory":[],"publicationCount":1673,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nicotinamide mononucleotide"],"phase":"marketed","status":"active","brandName":"NMN","genericName":"NMN","companyName":"Shanghai Cell Therapy Group Co.,Ltd","companyId":"shanghai-cell-therapy-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NMN (nicotinamide mononucleotide) replenishes cellular NAD+ levels to support mitochondrial function and energy metabolism. Used for Age-related metabolic decline, Mitochondrial dysfunction support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}